I’m trying this post again after deletion, sorry if the conversation has moved on by now.
I was shocked that the BMA’s medical ethics committee (MEC) which recommends ethical policy to the BMA has seemingly allowed a BMA conference policy vote position to become official BMA policy, and of a sufficiently well-supported standing that it can be presented to a judge in court... without apparently any scrutiny on this matter by the MEC? (that I can find from any googling)
www.bma.org.uk/what-we-do/committees/medical-ethics-committee/medical-ethics-committee-overview
I would be very happy to have pointed out to me anywhere publicly stating that the BMA’s MEC have in fact already scrutinised the experimental and in all likelihood permanent medical transitioning of kids and have considered the Bell case. I would be interested to see their thinking on this. It’s been a long-standing worry that the BMA MEC are so influential on medical practice yet have appeared not to have investigated this issue of transitioning of children and young people publicly.
It seems very strange though if the BMA executive team is supporting a policy position apparently derived from an annual conference vote as a basis their intervention in this case. Also given that Gillick is not threatened or trumped by the Bell case, it’s disappointing to see the BMA spending their resources on trying to intervene on a case that they seem not to understand sufficiently.
And disappointing in that you’d hope the BMA’s normal policy making process would defer such sensitive ethical issues for nuanced multidisciplinary exploration by their MEC- and that they would not take official BMA position from their annual conference floor which debates and votes on dozens of different issues each year in very short succession.
And surely the legal counsel to BMA, who may not be versed in ethical issues themselves, but do understand the law, are advising the BMA Executive team that Bell supports the proper application of Gillick. All of which makes it very hard to understand what the BMA leadership are looking to achieve here, and on whose behalf?
I guess it will emerge from the case in due course 